OUR APPROACH

Spring Bioscience takes a targeted and focused approach to building its product portfolio. First, we strategically select biomarkers that will be relevant for future high-value clinical tests or companion diagnostics. Second, we invest heavily in leading immunology technologies including rabbit monoclonal antibody development to deliver the highest quality information to researchers. Lastly, we complement a strong antibody product portfolio with a broad set of Immunohistochemistry (IHC) tools including detection systems, antibody arrays, recombinant proteins and more. In addition to our expertise in IHC many of our antibodies are further characterized by Western Blot, ELISA, and other applications as well as multiple host tissues including human and mouse/rat. Our products both those under development and those currently available are consistent with our mission to build essential tools for cancer researchers so that tomorrow's patients may benefit from today's innovations.

QUALITY FIRST

We maintain an ISO9001:2008 (ISO 9001) certified quality system assuring sustainable product quality and continuous improvement. Additionally, our reputation of collaboration with strategic partners including those with affiliates including Ventana Medical Systems, Genentech, and other Roche Group companies and our research customers speaks to our dedication to advancing the industry as a whole.

OUR CULTURE

Spring is a nimble and efficient group, and our culture is one of dialogue and collaboration with our customers and strategic partners. We look forward to assisting industry leaders enhance their research and diagnostic endeavors through the seamless supply of our specialized IHC product lines.